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Purpose of Review 
The recent emergence of single cell technologies has permitted unprecedented insight 
into the molecular drivers of fate choice in blood stem and progenitor cells.  This review 
gives a broad overview of current efforts to understand the molecular regulators of 
malignant HSCs at the single cell level. 
 
Recent Findings 
The large-scale adoption of single cell approaches has allowed extensive description of 
the transcriptional profiles and functional properties of single HSCs. These techniques are 
now beginning to be applied to malignant HSCs isolated directly from patients or from 
mouse models of malignancy. However, these studies have generally struggled to 
pinpoint the functional regulators of malignant characteristics, since malignant HSCs 
often differ in more than one property when compared to normal HSCs. Moreover, both 
normal and malignant populations are complicated by HSC heterogeneity.  
 
Summary 
Despite the existence of single cell gene expression profiling tools, relatively few 
publications have emerged. Here, we review these studies from recent years with a 
specific focus on those undertaking single cell measurements in malignant stem and 
progenitor cells. We anticipate this to be the tip of the iceberg, expecting the next 2-3 
years to produce datasets that will facilitate a much broader understanding of malignant 
HSCs. 
 




Over the last 5 years, there has been an explosion of new tools to study the biology of large 
numbers of single cells1,2.  Functional cell biology techniques have long been used to study 
single cells, but new molecular techniques have allowed the coupling of cellular and 
molecular heterogeneity3–6, adding unprecedented resolution to the concepts first 
investigated using cellular biology techniques.  
 
Functional heterogeneity in HSCs 
The existence of heterogeneity in hematopoietic stem cells (HSCs) has been well 
documented from a functional standpoint. In the 1960s, Becker, McCulloch and Till first 
alluded to the cellular heterogeneity of HSCs in colony forming unit spleen (CFU-S) 
assays7, a seminal in vivo assay which demonstrated that the output of hematopoietic 
progenitors varied considerably in their size, composition (the numbers and types of 
mature and primitive cells), time to detection and the number of secondary colonies they 
could give rise to. These differences were the first hint that heterogeneity was a feature 
of mammalian blood stem cells and came at a time when bone marrow transplantations 
were emerging as a clinical option8,9. Key experiments in the 1980s tracking HSCs using 
retroviral inserts as genetic marks for their progeny, provided the first formal evidence 
of variations in self-renewal durability and also reaffirmed differences in mature cell 
production, prompting the eventual description of lineage-biased HSCs10–13. Perhaps the 
greatest advance in deciphering the functional heterogeneity of HSCs was the 
introduction of single cell florescence activated cell sorting (FACS) for HSC purification14, 
which lead to single HSC sorting and transplantation assays15.  
 
The gold-standard assay for evaluating self-renewal is serial transplantation into 
myeloablated recipient mice16. Prior to the advent of single cell transplantations, limiting 
dilution assays were used to approximate the number of HSCs within a test cell 
suspension. Results were commonly quantified using the competitive repopulating unit 
(CRU)17 since it could not be formally determined that a single cell gave rise to the donor 
graft. This uncertainty was alleviated when single cell transplantations formally 
demonstrated that one cell could on its own be isolated and transplanted into recipients 
to give rise to long-term, multi-lineage haematopoiesis15.  This remains the best means 
for assessing HSC function with respect to lineage output, expansion capacity and long-
term self-renewal durability.  
 
However, single cell transplantations have several limitations. The first of these is that it 
assesses what an HSC can do in a stressed environment, as opposed to what it does do 
under homeostatic conditions. The second is that it does not test how HSCs interact as a 
population to maintain the balance of cellular outputs. These issues are at least partially 
overcome by genetic barcoding studies where bulk HSPCs can be transplanted together 
and tracked individually18. However, these assays are still transplantation-based and are 
further limited by needing an in vitro culture period, meaning that the culture itself (or 
integration site of the barcode) could add bias to the population. Moreover, sequence 
detection limits could also add bias, as it cannot conclusively determine absence of 
contribution or disappearance of a clone in longitudinal studies.  More advanced 
endogenous barcoding approaches have now been undertaken where HSCs are traced 
using reporter mice19 or genetic recombination is used to mark cells in vivo without any 
additional manipulation1,19,20 .  
 
It is clear from the above studies that understanding HSC heterogeneity has been a 
longstanding goal of the field, likely due to its implications for understanding the 
evolution of the immune system and the development of aberrant haematopoiesis, e.g. 
age-related clonal haematopoiesis (ARCH) and leukemia.  HSC subtypes have been 
described in mice based on differences in their self-renewal durability and mature cell 
production21–24, and this has prompted efforts to prospectively identify individual 
subtypes25–27. Cumulatively, efforts have produced overall HSC purities of >50% and 
several enrichment strategies for enriching various subtypes, setting the stage for studies 
to define the molecular programme governing HSC subtypes (both normal and 
malignant).  This increased ability to purify HSCs and the concomitant development of 
robust global gene expression tools in single cells28 offer an obvious solution to this 
longstanding problem. This review summarises recent efforts in this space. 
 
Molecular heterogeneity in HSCs 
Single cell molecular profiling of HSC and progenitors has already revealed a number of 
findings that were previously unattainable using bulk populations. Unbiased approaches 
such as RNAseq have identified new genes (and associated pathways) involved in stem 
cell function and lineage commitment29,30. These same techniques unveiled the 
heterogeneity within various progenitor compartments30, and confirmed that the 
molecular process by which stem cells differentiate is a gradual process (i.e., a continuum) 
rather than a stepwise progression though progressively more differentiated 
progenitors31. Importantly, studies that have profiled HSCs all converge on the 
description of significant heterogeneity within the population, but the utility of such a 
finding is unclear. 
 
An important factor when considering “heterogeneity” is the difference between 
informative heterogeneity (biologically driven variations that result in functional 
differences), and generic heterogeneity (differences driven by processes occurring in all 
cell types (e.g., cell cycle28).  Another consideration is the extent of heterogeneity that is 
actually driven by technical noise: if it were possible to sequence the same cell many 
times, there would be technical drop-out of genes and this would differ between 
experiments, adding an artificial “heterogeneity” to the population. Finally, and perhaps 
least obvious, there is yet another type of heterogeneity hidden amongst molecular 
studies of purified HSCs – that of non-HSC contaminants.   Unlike transplantation assays, 
where non-HSCs do not read out and are therefore not able to confuse the description of 
heterogeneity, molecular assays will generate 100 gene expression profiles from 100 
cells.  When populations are of a low purity eg 5 or 10% and single cell molecular studies 
are undertaken, it becomes incredibly difficult to assign a specific molecular programme 
to a specific cell function.  The reality in such cases is that 90-95% of the molecular 
programmes are NOT the cell of interest and, unlike long term cell biological assays where 
non-HSCs are no longer represented, these represent a significant confounder for single 
cell molecular biology studies (Figure 1).   
 
The latter issue can be partially circumvented by linking functional single cell HSC assays 
to molecular assays. Flow cytometric index sorting records the fluorescence intensity of 
each immunophenotypic marker, thereby allowing the retrospective coupling of markers 
and output. This has been combined with single cell functional in vitro3 and in vivo4 assays 
to refine the effectiveness of sort panels. Such approaches are already starting to 
demonstrate their utility in the human setting as well with in vitro functional readouts of 
human HSCs being linked to molecular profiles by index-sorting32. We predict that the 
next several years will yield many similar studies, but an additional challenge looms when 
trying to understand how single HSCs are corrupted from a molecular standpoint to drive 
disease. 
 
HSC heterogeneity and malignancy 
Malignant HSCs share many of the same cellular processes and pathways as normal HSCs, 
but some processes must be hijacked to enable increased proliferation and/or a 
differentiation block.  Therefore, it becomes important to not simply think of malignant 
HSCs as a completely separate cell state compared to normal HSCs, but rather a very close 
molecular relative. A reductive approach leads many researchers to study highly purified 
populations of HSCs in mouse models bearing a single genetic change. Since many myeloid 
malignancies have now been extensively sequenced and numerous malignancy-driving 
mutations identified, a great deal of effort has focused on establishing the mechanism by 
which these mutations initiate and sustain disease.  
 
It is in studying the molecular effects of specific mutations on HSCs that mouse models 
are particularly useful, largely because we can isolate HSCs at a much higher frequency 
compared to human, and additionally mouse models can be 100% mutant, thereby 
avoiding complications of intra-patient HSC heterogeneity in mutational state33. From 
mouse models we have determined that there are common pathways driving shared 
disease features, (e.g., hyperactivation of the JAK/STAT signalling pathway leads to a 
proliferative advantage and can be achieved though mutations in JAK1,2, STAT1,3,5, MPL, 
CALR, LNK and CBL)34.  
 
Taking advantage of these mouse models, many studies have now analysed the 
transcriptional profiles of mutant mouse models at the bulk level and it has become clear 
that progress is impeded by two main issues: 1) population heterogeneity (not purifying 
the HSC fraction) and 2) an inability to observe co-expression (or not) in the same cell.  
Single cell approaches give this added resolution when used appropriately, although the 
number of published transcriptional profiles in mouse models of hematological 
malignancies at the single cell level remains limited (Table 1).  
 
Since haematological malignancies often have more than one driver35, and several aspects 
of HSCs can be affected by each mutation (e.g., JAK2 mutations alter cell cycle status, 
proliferation, differentiation and HSC self-renewal), it remains difficult to ascribe 
individual properties of disease when studying single mutations in isolation.  For these 
reasons, many recent studies have generated mouse models to study combinations of 
mutations36–42. 
 
However as with single mutant models, there is a paucity of single cell molecular assays 
carried out in these models.  In these limited instances, it is clear that single cell 
approaches can make novel discoveries that are not possible to uncover by studying 
single mutations alone. To cite one example, in a study of a mouse model of CN-AML43, 
where DNMT3a and FLT3ITD mutations were combined, single cell RNA-seq was 
performed on c-Kit+ leukemic splenocytes to determine whether c-Myc expression could 
be a biomarker for FLT3ITD (it could not). The heterogeneity of AML tumors, coupled with 
incomplete penetrance of the mutations, made this question unanswerable at the bulk 
level, demonstrating the power of single cell approaches to reveal new biology.  
 
Integrating functional and molecular heterogeneity in malignant HSCs 
Combining the latest advances in single cell techniques with recently developed mouse 
models, it is now possible to understand more deeply the precise mechanisms involved 
in malignant HSC self-renewal.  To undertake such studies, simplified disease models are 
useful.  Myeloproliferative neoplasms (MPNs) are a particularly tractable disease for 
studying leukemogenesis because they are a relatively simple disease with a low 
mutational burden (the vast majority of patients have fewer than 3 mutations44). The 
most common mutation in MPNs is JAK2 V617F and a number of mouse models have been 
developed to understand how one mutation can be associated with multiple disease 
subtypes45, ARCH46,47, or potentially in undetectable transient clones. These mouse 
models all recapitulate some hematological aspects of disease (e.g., raised RBCs or 
platelets), but - like MPNs in patients - differ from each other in several respects.  The first 
gene expression profiles of JAK2 V617F HSCs were performed at the bulk level and the 
only changes that could be observed (if any) pointed to differences in cell cycle 
regulators48, which is only one of the properties altered in malignant HSCs. 
 
Single cell approaches in combinatorial mouse models can help resolve this issue.  As it 
stands, it is impossible to know a priori which molecules are involved with each altered 
property in a single-mutant mouse model (e.g., hyper-proliferation, dormancy, HSC self-
renewal changes or differentiation patterns). We recently tried to address these issues by 
crossing JAK2 V617F mice with TET2 KO mice48** (TET2 is an epigenetic regulator that is 
the most common co-mutation with JAK2 V617F).  Since TET2 KO mice have no 
erythrocytic phenotype and display an HSC self-renewal advantage, the comparison of 
single-mutant and double-mutant mice allowed us to study 4 unique states: normal 
unperturbed WT HSCs, hyper-proliferating HSCs with a self-renewal defect (JAK2V671F 
single-mutant HSCs), HSCs with a self-renewal advantage and relatively normal 
proliferation/differentiation (TET2 single-mutant HSCs), and JAK2/TET2 double mutant 
HSCs.  The first observation we made was that the double-mutant HSCs represented some, 
but not all aspects of each mutations – HSCs had normal self-renewal but remained hyper-
proliferative and their progeny had the differentiation abnormalities associated with the 
JAK2V617F mutation.  
This series of models permitted us to ask a direct question about the regulation of 
malignant HSC self-renewal: which genes are responsible for the JAK2 V617F self-renewal 
defect? We answered this by profiling 43 established HSC regulators, in combination with 
single cell functional assays in each of these models. This revealed new candidate 
molecules from which Bmi1, Pbx1 and Meis1 appeared to have functional consequences 
on malignant HSC self-renewal. Thus our study exemplified how single cell approaches, 
in combination with allelic series, can be used to unveil new biological information not 
possible with bulk studies.  Applying similar approaches more broadly across new models 
will help us understand the molecular networks driving each individual property of 
malignant HSCs.  
 
Human patient HSCs 
The goal of understanding the molecular networks governing malignant HSC self-renewal 
is to apply the findings to treating patients with cancer. It is therefore desirable for similar 
molecular studies to be performed on patient samples. Such studies are limited, however, 
owing to a number of factors: firstly, as mentioned above the efficiency of sorting 
functional human HSCs using immunophenotypic markers is much lower than in mouse 
(<10% in human >50% in mouse), which has obvious consequences for downstream gene 
expression analyses. Secondly, disease burden is variable in patient samples and 
currently there are no markers in hematological malignancies for prospectively 
identifying mutant versus non-mutant cells meaning that samples would be different 
mixtures of malignant and non-malignant HSCs. Thirdly, patients are extremely 
heterogeneous and vary in a number of aspects related to disease such as the 
combinations of mutations they have49, the order of mutation acquisition50, and 
differences in lifestyle; smoking, diet, etc51. These factors each add a layer of complexity 
to the study of the human HSCs and their molecular networks.   
 
One of the first studies to try and tackle this latter issue took a clonal approach to 
distinguish mutant and non-mutant clones retrospectively33. Growing and genotyping 
erythroid colonies from a single patient enabled transcriptional profiling of non-mutant, 
heterozygous JAK2V617F and homozygous JAK2V617F cells, thereby controlling for 
intra-patient heterogeneity.  One of the most important revelations of this paper, 
however, was that across 36 patients studied in this way, colony transcriptomes clustered 
much more strongly within the patient than with the individual mutations, confirming 
that intra-patient heterogeneity is a substantial confounding variable in such studies.  
Also, transcriptomes could only be collected from the differentiated progeny of HSCs 
rather than the HSCs themselves, so only so much could be learned about the HSC 
transcriptome itself. 
 
To try and address the issue of directly measuring a mutant HSC transcriptome, 
developments in single cell molecular biology again proved useful.  The most impressive 
effort to date coupled single cell transcriptomics with detection of the BCR-ABL transgene 
in chronic myeloid leukemia (CML) patients by multi-plexing BCR-ABL-specific primers 
at the reverse transcription and amplification steps of the scRNA-seq protocol2**. This 
technology allows sensitive and specific detection of the BCR-ABL mutation 
simultaneously with unbiased whole transcriptome analysis of the same HSC, thereby 
permitting a molecular comparison of mutant to non-mutant HSCs in the same individual. 
After validating the nested priming approach for genotyping cells from the transcriptome, 
this study compared HSCs from normal individuals to BCR-ABL+ HSCs and BCR-ABL- 
HSCs from CML patients.   
 
Perhaps the most interesting aspect of the Giustacchini study was their comparison of 
normal HSCs to non-mutant HSCs in the CML patient which showed striking differences 
in the gene signatures. Non-mutant HSCs from CML patients had higher expression of 
genes associated with microenvironmental factors IL-6, STAT5, TGF-β and TNF-α. As 
inflammation is a suspected suppressor of HSC function52,53, this suggests that in humans, 
leukemic stem cells and their progeny might be creating their own self-supporting niche54 
that suppresses normal non-mutant HSCs.  Moreover, response of patients to TKI 
treatment could be predicted by the inflammatory signalling changes observed in non-
mutant HSCs – again something that could only be detected by being able to study these 
HSCs separately. 
 
However BCR-ABL, unlike other mutations, only requires a single genotyping assay to be 
developed for all patients, loss-of-function mutations would be less straightforward to 
genotype via the transcriptome in a robust and scalable manner. Efforts to scale this to 
more mutations have nevertheless begun in diseases such as AML55 but the efficiencies 
are not yet at a point where there is a high confidence in calling the absence of a mutation. 
To address this issue Rodriguez-Meira et al56* have developed a technique combining 
scRNA-seq with targeted mutation sequencing from gDNA and cDNA, allowing much 
more accurate calling of mutations for which cDNA expression is undetectable or highly 
allelic-biased. If such approaches were broadly applicable across many mutations in a 
reliable and quantitative fashion, this would revolutionise the field of patient HSC 
analysis.   
 
Key points: 
 Functional heterogeneity of HSCs has been well established, first alluded to in the 
1960s and robustly supported by single cell functional assays  
 Single cell gene expression assays are trendy but biological, generic and 
contaminating heterogeneity must be considered when interpreting  
 Groups are now combining functional and molecular techniques to study 
mutation combinations and malignant HSC properties in mouse and human. 
 The stage is set for an explosion of papers using single-cell techniques to 
investigate haematological malignancies 
 
Concluding thoughts 
Single cell approaches are leading the way to a much more profound understanding of the 
molecular networks governing malignant HSC fate choice. New mouse models are 
constantly improving our understanding of the common pathways driving malignancy, 
but a gap remains in our understanding around the interplay between these single 
mutations and additional genetic and non-genetic factors. Many patients have 
combinations of mutations, and while several groups have started modelling these 
interactions36–42, very few have studied the molecular biology of HSCs at the single cell 
level48. 
 
Studies in recent years have demonstrated that the hematopoietic microenvironment can 
have a substantial impact upon the cellular output of normal and malignant HSCs54. 
Perturbation of the hematopoietic system by a number of different exogenous insults 
likely impacts the growth and expansion of HSC clones with different mutations. Recent 
evidence shows that infections can affect the HSCs directly57–60. 
  
Beyond understanding the molecular nature of malignancy, we envisage a growing need 
to monitor differential HSC clonal dynamics in humans to understand how a single clone 
can emerge to drive a leukaemia.  Recent evidence suggests that using somatic mutation 
acquisition as an endogenous barcode might be useful for studying the relative 
contribution of clones over the lifetime of an individual61*. At present, such techniques 
are not possible in large numbers of humans, but if similar approaches could be devised, 
studying how clonal dynamics change upon acquisition of oncogenic mutations and 
exposure to environmental or endogenous stresses may well become a fruitful line of 
enquiry.  Until then, in vitro approaches and mouse models will be heavily relied upon. 
The emergence of these new single cell and clonal technologies has generated significant 
enthusiasm amongst researchers and clinicians trying to understand the molecular 
differences between malignant and non-malignant cells, including a more complete 
understanding of clonal competition during disease establishment, maintenance and 
progression.  As mentioned above, the first studies are only now starting to emerge as 
technologies converge; the next three to five years promise to deliver an increasingly 
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Figure 1:  Selectivity of functional assays reduces experimental noise in the description of HSC 
heterogeneity.  Depicted on the left is a single cell functional assay where 5 input cells are each transplanted 
into a single recipient mouse and analysed for the presence of an HSC.  In this case, 3 cells do not read out and 
a “red” HSC subtype and a “blue” HSC subtype are easily compared.  On the right are a similar set of 5 input 
cells where each cell is subjected to single cell gene expression profiling – all 5 cells generate a molecular 
profile that is unique, but it is unclear which profiles belong to HSCs and which belong to non-HSCs, making 
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JAK2  ESLAM HSC scRNA-seq Sc HSC liquid 
culture 
Young vs old JAK2 V617F HSCs; in 
aged HSCs increased p53, 
accompanied by functional decline 
Loughran et 
al 2017 JEM 63 










Mbd3/NuRD complex represses B 
cell transcriptional program, 
preventing lymphoid progenitors 
from undergoing B cell lineage 
commitment 
Herault et al 
2017 
Nature64* 
BCR-ABL GMP scRNA-seq & 
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Sc CFCs, in situ 
imaging 
Spatial organisation of GMPs; 
clusters formed in emergency 
myelopoesis and BCR-ABL mutant 
have enhanced self renewal 
networks 
Guo et al 
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Stem Cell65 
MLL-AF9 LSK, LSK−, 
LS−K, LS−K− 
Sc-qPCR None Leukemia cells are intrinsically 
distinct from any wild-type 
lineages, Ezh2 is overexpressed in 
the more highly proliferative 
leukemia cells 
Double Mutant 
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ESLAM HSC Sc-qPCR Sc HSC liquid 
culture  
Molecular regulators of JAK2 
V617F stem cell defect identified 
as Bmi1, Meis1, and, Pbx1. 
 
Table 1: Table of studies which have used single-cell molecular techniques to 
study mouse models of haematological malignancies.  
